National Bank of Canada FI Purchases 4,784 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

National Bank of Canada FI grew its position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 639.6% during the fourth quarter, Holdings Channel reports. The institutional investor owned 5,532 shares of the biotechnology company’s stock after purchasing an additional 4,784 shares during the quarter. National Bank of Canada FI’s holdings in Arcturus Therapeutics were worth $94,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. Charles Schwab Investment Management Inc. raised its stake in Arcturus Therapeutics by 1.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 197,622 shares of the biotechnology company’s stock valued at $4,587,000 after acquiring an additional 3,224 shares during the period. BNP Paribas Financial Markets increased its stake in shares of Arcturus Therapeutics by 954.7% in the third quarter. BNP Paribas Financial Markets now owns 15,831 shares of the biotechnology company’s stock worth $367,000 after purchasing an additional 14,330 shares in the last quarter. Verition Fund Management LLC bought a new stake in shares of Arcturus Therapeutics in the third quarter valued at approximately $420,000. Geode Capital Management LLC lifted its stake in shares of Arcturus Therapeutics by 1.1% during the 3rd quarter. Geode Capital Management LLC now owns 551,798 shares of the biotechnology company’s stock valued at $12,810,000 after buying an additional 5,789 shares in the last quarter. Finally, Franklin Resources Inc. boosted its holdings in Arcturus Therapeutics by 54.6% in the 3rd quarter. Franklin Resources Inc. now owns 103,936 shares of the biotechnology company’s stock worth $2,412,000 after buying an additional 36,714 shares during the period. Institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Stock Up 3.7 %

Shares of NASDAQ ARCT opened at $9.70 on Friday. The stock’s 50-day simple moving average is $13.89 and its two-hundred day simple moving average is $16.89. Arcturus Therapeutics Holdings Inc. has a twelve month low of $8.04 and a twelve month high of $45.00. The firm has a market capitalization of $263.06 million, a P/E ratio of -4.37 and a beta of 3.41.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings data on Thursday, March 6th. The biotechnology company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.78). Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. The company had revenue of $22.77 million during the quarter, compared to the consensus estimate of $44.64 million. As a group, research analysts anticipate that Arcturus Therapeutics Holdings Inc. will post -2.22 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on ARCT shares. HC Wainwright reissued a “buy” rating and set a $60.00 target price on shares of Arcturus Therapeutics in a report on Thursday. Canaccord Genuity Group decreased their price objective on Arcturus Therapeutics from $74.00 to $68.00 and set a “buy” rating on the stock in a research note on Monday, March 10th. BTIG Research set a $48.00 target price on Arcturus Therapeutics and gave the stock a “buy” rating in a research note on Monday, March 10th. Wells Fargo & Company decreased their price target on Arcturus Therapeutics from $58.00 to $50.00 and set an “overweight” rating on the stock in a research report on Friday, March 7th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Arcturus Therapeutics in a report on Friday, March 7th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $59.20.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.